A comprehensive review of COVID-19 treatment

Author:

Afshar Zeinab,Babazadeh Arefeh,Javanian Mostafa,Barary Mohammad,Rekha Vasigala,Ebrahimpour Soheil

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

Subject

General Medicine

Reference68 articles.

1. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19(3):149-50 https://doi.org/10.1038/d41573-020-00016-0;

2. Mohseni Afshar Z, Ebrahimpour S, Javanian M, et al. Vital role of chest CT in diagnosis of coronavirus disease 2019 (COVID-19). Caspian J Intern Med 2020;11:244-9. https://europepmc.org/article/med/32874430;

3. Ali SA, Baloch M, Ahmed N, Ali AA, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat. J Infect Public Health 2020;13(4):644-6. https://doi.org/10.1016/j.jiph.2020.02.033;

4. Lee P-I, Hsueh P-R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect 2020 ;53(3):365-7 https://doi.org/10.1016/j.jmii.2020.02.001;

5. Javanian M, Masrour-roudsari J, Bayani M, Ebrahimpour S. Coronavirus disease 2019 (COVID-19): What we need to know. Caspian J Intern Med 2020;11(2):235-6;

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3